Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to ...

(NASDAQ: REGN) today announced that the European Commission (EC) has granted conditional marketing approval of Lynozyfic™ (linvoseltamab) to treat adults with relapsed and refractory (R/R) multiple ...

“Regeneron is an American success story, with over 80 percent of our workforce and assets in the U.S. and all of our FDA-approved medicines invented in our New York laboratories. Our innovative ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The Zacks Consensus Estimate for revenues is pegged at $3.25 billion ...

April 22 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer Fujifilm Diosynth, potentially ...

$3 billion FUJIFILM deal will nearly double Regeneron’s large-scale U.S. biologics manufacturing capacity over the next decade. Regeneron adds 7,000+ U.S. jobs in five years, with $7B+ in ...

New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron’s biologic medicines and support high-paying jobs ...

Regeneron announced a major expansion of its biologics manufacturing capabilities through a new partnership with FUJIFILM Diosynth Biotechnologies. According to the company, the deal will nearly ...

Under a new 10-year agreement, Regeneron will pay CDMO powerhouse Fujifilm Diosynth Biotechnologies more than $3 billion to help manufacture bulk drug product for its commercial biologics in the ...

Regeneron Pharmaceuticals signed a new manufacturing-and-supply agreement with Fujifilm Diosynth Biotechnologies to double its large-scale manufacturing in the U.S. Regeneron's new investment with ...

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and ...

FUJIFILM Diosynth Biotechnologies signed a 10-year manufacturing supply agreement, valued at over $3 billion, with Regeneron Pharmaceuticals to provide U.S.-based production of its biologic medicines.